Physician profile
Westley E Raborn
NPI 1013910082
$467.20
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $111.53 | 2019-2020 | |
| Pfizer INC. | $102.05 | 2019-2020 | |
| Amgen INC. | $68.48 | 2019-2020 | |
| Abbvie INC. | $37.79 | 2019 | |
| Novo Nordisk INC | $30.18 | 2019-2020 | |
| Amarin Pharma, INC. | $24.01 | 2019 | |
| Lilly USA, LLC | $22.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $22.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.81 | 2019 | |
| Sanofi Pasteur INC. | $13.62 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Westley Raborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.